Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib + Carboplatin + Paclitaxel in Advanced Malignancies
NCT03430882Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sapanisertib in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence and grade of adverse events, Maximum Tolerated Dose up to 21 days and 3 more. Started Mar 2018; status: completed.
02
Drugs
sapanisertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03430882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430882.